Zobrazeno 1 - 10
of 21
pro vyhledávání: '"II Kostroma"'
Autor:
EV Karyagina, S.V. Gritsaev, AV Chechetkin, IM Zapreeva, II Kostroma, Elena I. Stepchenkova, N.Yu. Semenova, S.S. Bessmeltsev, AA Zhernyakova, Zh.Yu. Sidorova
Publikováno v:
Clinical oncohematology. 14:73-79
Background. Autologous hematopoietic stem cell transplantation (auto-HSCT) is an indispensable treatment stage in patients with newly diagnosed multiple myeloma (MM) who are, based on age and health status, eligible for high-dose chemotherapy with su
Autor:
AV Chechetkin, Svetlana Pavlovna Svitina, S.I. Kapustin, II Kostroma, Zh.Yu. Sidorova, Zh V Chubukina, S.S. Bessmeltsev, AA Zhernyakova, S.V. Gritsaev
Publikováno v:
Clinical oncohematology. 14:340-346
Aim. To assess polymorphism value of interleukins (IL6, IL1B, IL10) and tumor necrosis factor α (TNF) genes in multiple myeloma (MM) patients who received autologous hematopoietic stem cell transplantation (auto-HSCT). Materials & Methods. The study
Autor:
II Kostroma, AV Chechetkin, Elena I. Stepchenkova, S.P. Svitina, AA Zhernyakova, Zh.Yu. Sidorova, N.Yu. Semenova, S.S. Bessmeltsev, S.V. Gritsaev, R.R. Sabitova
Publikováno v:
Clinical oncohematology. 14:333-339
Aim. To assess the rate of cases without antitumor response quality improvement after high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM). To assess the rate of allelic variants o
Autor:
II Kostroma, EYu Ilyushkina, EV Karyagina, RR Miftakhova, Transfusiology, ya Sovetskaya str., Saint Petersburg, Russian Federation, SS Bessmeltsev, TL Shelkovskaya, ZhL Stolypina
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 13, Iss 1, Pp 25-32 (2019)
Background. Daratumumab is IgG1-K humanized anti-CD38 monoclonal antibody. It has a direct impact on tumor and immunomodulatory effect. Aim. To assess the efficacy of daratumumab monotherapy in patients with progressive, and relapsed/refractory multi
Autor:
II Kostroma, AV Chechetkin, AA Zhernyakova, IM Zapreeva, V.N. Chebotkevich, Gritsaev Sv, SS Bessmeltsev
Publikováno v:
Clinical oncohematology. 13:289-294
Background. There exist different data on how the administration of granulocyte colony-stimulating factor (G-CSF) after autologous hematopoietic stem cell transplantation (auto-HSCT) affects the duration of post-transplantation agranulocytosis in mul
Autor:
Tiranova Sa, EV Karyagina, Gritsaev Sv, ZhV Chubukina, Irina Martynkevich, SS Bessmeltsev, II Kostroma, Transfusiology, ya Sovetskaya str., Saint Petersburg, Russian Federation, AA Zhernyakova, AV Chechetkin, IM Zapreeva
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 12, Iss 3, Pp 282-288 (2019)
Background. In multiple myeloma (MM) treatment a single autologous hematopoietic stem cell transplantation (auto-HSCT) is preceded by conditioning regimens aimed at intensifying cytoreductive effect. In the course of ongoing search for combined condi
Autor:
Gritsaev Sv, SS Bessmeltsev, Transfusiology, ya Sovetskaya str., Saint Petersburg, Russian Federation, Tiranova Sa, ZhV Chubukina, II Kostroma, AV Chechetkin, IM Zapreeva, AA Zhernyakova, NYu Semenova
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 12, Iss 1, Pp 32-36 (2018)
Background. The success of autologous hematopoietic stem cell transplantation (auto-HSCT) depends on the speed of transplant engraftment which in turn is affected by the count of harvested and infused hematopoietic stem cells (HSC). Aim. To identify
Autor:
AV Chechetkin, II Kostroma, Gritsaev Sv, NYu Semenova, IM Zapreeva, SS Bessmeltsev, ZhV Chubukina, A V Shmidt, Andrey Garifullin, AA Kuzyaeva, Balashova Va, SV Voloshin, AYu Kuvshinov, Transfusiology, ya Sovetskaya str., Saint Petersburg, Russian Federation, VI Rugal
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 11, Iss 4, Pp 368-377 (2018)
Aim. To establish correlation between CD34+ autologous hematopoietic stem cell (HSC) count and colony-forming units (CFU) in the same peripheral blood apheresis product samples before and after cryopreservation in multiple myeloma and lymphoma patien
Autor:
IM Zapreeva, NA Potikhonova, EV Litvinskaya, Tiranova Sa, SV Gritsaev, K M Abdulkadyrov, AA Kuzyaeva, II Kostroma, LV Stel’mashenko, IS Martynkevich
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 9, Iss 1, Pp 48-53 (2016)
Aim. The aim of this paper is to evaluate the effectiveness of low dose cytarabine (Ara-C) combined with cladribine for the treatment of relapsed or refractory acute myeloid leukemia (AML) and to determine clinical and lab factors associated with res
Publikováno v:
Clinical oncohematology. 8:413-419